iqvia biotech ltd.
iqvia biotech ltd. Company Information
Company Number
03299057
Website
https://www.iqviabiotech.comRegistered Address
3 forbury place, 23 forbury road, reading, RG1 3JH
Industry
Research and experimental development on biotechnology
Telephone
-
Next Accounts Due
September 2024
Group Structure
View All
Shareholders
iqvia ltd 100%
iqvia biotech ltd. Estimated Valuation
Pomanda estimates the enterprise value of IQVIA BIOTECH LTD. at £180.4m based on a Turnover of £86m and 2.1x industry multiple (adjusted for size and gross margin).
iqvia biotech ltd. Estimated Valuation
Pomanda estimates the enterprise value of IQVIA BIOTECH LTD. at £183.3m based on an EBITDA of £20.7m and a 8.86x industry multiple (adjusted for size and gross margin).
iqvia biotech ltd. Estimated Valuation
Pomanda estimates the enterprise value of IQVIA BIOTECH LTD. at £628.9m based on Net Assets of £292.4m and 2.15x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Iqvia Biotech Ltd. Overview
Iqvia Biotech Ltd. is a live company located in reading, RG1 3JH with a Companies House number of 03299057. It operates in the research and experimental development on biotechnology sector, SIC Code 72110. Founded in January 1997, it's largest shareholder is iqvia ltd with a 100% stake. Iqvia Biotech Ltd. is a mature, large sized company, Pomanda has estimated its turnover at £86m with rapid growth in recent years.
Upgrade for unlimited company reports & a free credit check
Iqvia Biotech Ltd. Health Check
Pomanda's financial health check has awarded Iqvia Biotech Ltd. a 5 rating. We use a traffic light system to show it exceeds the industry average on 7 measures and has 3 areas for improvement. Company Health Check FAQs
7 Strong
1 Regular
3 Weak
Size
annual sales of £86m, make it larger than the average company (£3.5m)
£86m - Iqvia Biotech Ltd.
£3.5m - Industry AVG
Growth
3 year (CAGR) sales growth of 32%, show it is growing at a faster rate (14.1%)
32% - Iqvia Biotech Ltd.
14.1% - Industry AVG
Production
with a gross margin of 36.4%, this company has a higher cost of product (53%)
36.4% - Iqvia Biotech Ltd.
53% - Industry AVG
Profitability
an operating margin of 24% make it more profitable than the average company (-0.4%)
24% - Iqvia Biotech Ltd.
-0.4% - Industry AVG
Employees
with 170 employees, this is above the industry average (44)
170 - Iqvia Biotech Ltd.
44 - Industry AVG
Pay Structure
on an average salary of £83k, the company has an equivalent pay structure (£77.9k)
£83k - Iqvia Biotech Ltd.
£77.9k - Industry AVG
Efficiency
resulting in sales per employee of £506.1k, this is more efficient (£136.2k)
£506.1k - Iqvia Biotech Ltd.
£136.2k - Industry AVG
Debtor Days
it gets paid by customers after 21 days, this is earlier than average (51 days)
21 days - Iqvia Biotech Ltd.
51 days - Industry AVG
Creditor Days
its suppliers are paid after 38 days, this is quicker than average (70 days)
38 days - Iqvia Biotech Ltd.
70 days - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- - Iqvia Biotech Ltd.
- - Industry AVG
Cash Balance
has cash to cover current liabilities for 21 weeks, this is less cash available to meet short term requirements (35 weeks)
21 weeks - Iqvia Biotech Ltd.
35 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 7.5%, this is a lower level of debt than the average (50%)
7.5% - Iqvia Biotech Ltd.
50% - Industry AVG
IQVIA BIOTECH LTD. financials
Iqvia Biotech Ltd.'s latest turnover from December 2022 is £86 million and the company has net assets of £292.4 million. According to their latest financial statements, Iqvia Biotech Ltd. has 170 employees and maintains cash reserves of £9.5 million as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 86,033,000 | 59,373,000 | 43,162,000 | 37,329,000 | 30,698,000 | 29,959,000 | 24,824,000 | 15,843,000 | 13,610,000 | 14,432,302 | 14,794,620 | 12,205,800 | 8,648,462 | |
| Other Income Or Grants | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Cost Of Sales | 54,708,000 | 40,707,000 | 32,503,000 | 28,881,000 | 24,000,000 | 23,526,000 | 17,731,000 | 9,081,000 | 9,009,000 | 9,411,812 | 9,404,433 | 8,294,248 | ||
| Gross Profit | 31,325,000 | 18,666,000 | 10,659,000 | 8,448,000 | 6,698,000 | 6,433,000 | 7,093,000 | 6,762,000 | 4,601,000 | 5,020,490 | 5,390,187 | 3,911,552 | ||
| Admin Expenses | 10,656,000 | 4,677,000 | 4,126,000 | 2,668,000 | 2,336,000 | 2,599,000 | 2,643,000 | 3,375,000 | 3,773,000 | 4,502,731 | 4,547,834 | 4,221,004 | ||
| Operating Profit | 20,669,000 | 13,989,000 | 6,533,000 | 5,780,000 | 4,362,000 | 3,834,000 | 4,450,000 | 3,387,000 | 828,000 | 517,759 | 842,353 | -309,452 | 672,630 | |
| Interest Payable | 0 | 7,000 | 11,000 | 35,000 | 28,000 | 21,000 | 7,000 | 1,000 | 0 | 0 | 0 | 378 | 0 | |
| Interest Receivable | 570,000 | 5,000 | 49,000 | 170,000 | 107,000 | 11,000 | 10,000 | 8,000 | 0 | 598 | 0 | 119 | 1,341 | |
| Pre-Tax Profit | 29,827,000 | 20,333,000 | 6,571,000 | 5,910,000 | 4,441,000 | 3,824,000 | 4,453,000 | 3,394,000 | 828,000 | 518,357 | 842,353 | -309,711 | 673,971 | |
| Tax | -5,109,000 | -2,714,000 | -1,250,000 | -1,121,000 | -851,000 | -96,000 | -68,000 | 9,000 | -95,000 | -117,236 | -206,898 | 70,347 | -202,304 | |
| Profit After Tax | 24,718,000 | 17,619,000 | 5,321,000 | 4,789,000 | 3,590,000 | 3,728,000 | 4,385,000 | 3,403,000 | 733,000 | 401,121 | 635,455 | -239,364 | 471,667 | |
| Dividends Paid | 0 | 0 | 19,000,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Retained Profit | 24,718,000 | 17,619,000 | -13,679,000 | 4,789,000 | 3,590,000 | 3,728,000 | 4,385,000 | 3,403,000 | 733,000 | 401,121 | 635,455 | -239,364 | 471,667 | |
| Employee Costs | 14,115,000 | 11,941,000 | 9,259,000 | 8,220,000 | 6,808,000 | 5,616,000 | 4,665,000 | 5,492,000 | 4,949,000 | 5,307,395 | 5,072,390 | 4,427,923 | 3,107,026 | |
| Number Of Employees | 170 | 167 | 152 | 142 | 130 | 115 | 145 | 110 | 105 | 111 | 105 | 98 | 74 | |
| EBITDA* | 20,687,000 | 14,012,000 | 6,628,000 | 6,044,000 | 4,534,000 | 4,022,000 | 4,658,000 | 3,537,000 | 104,427,000 | 614,679 | 932,103 | -191,271 | 762,438 |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 11,000 | 29,000 | 52,000 | 173,000 | 266,000 | 414,000 | 562,000 | 652,000 | 158,000 | 229,332 | 223,341 | 155,821 | 163,725 | 215,195 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments & Other | 249,685,000 | 254,485,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debtors (Due After 1 year) | 67,000 | 59,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Fixed Assets | 249,763,000 | 254,573,000 | 52,000 | 173,000 | 266,000 | 414,000 | 562,000 | 652,000 | 158,000 | 229,332 | 223,341 | 155,821 | 163,725 | 215,195 |
| Stock & work in progress | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 642,896 | 0 |
| Trade Debtors | 5,112,000 | 3,427,000 | 6,318,000 | 763,000 | 1,152,000 | 1,804,000 | 827,000 | 500,000 | 1,607,000 | 3,368,493 | 4,628,758 | 3,077,710 | 1,682,399 | 1,838,007 |
| Group Debtors | 51,511,000 | 25,123,000 | 11,867,000 | 8,309,000 | 7,660,000 | 4,882,000 | 2,259,000 | 6,253,000 | 0 | 10,887 | 0 | 1,464 | 0 | 0 |
| Misc Debtors | 62,000 | 157,000 | 226,000 | 3,532,000 | 2,221,000 | 2,832,000 | 193,000 | 132,000 | 85,000 | 118,851 | 155,427 | 140,036 | 45,194 | 0 |
| Cash | 9,501,000 | 2,816,000 | 0 | 16,450,000 | 14,873,000 | 9,653,000 | 7,570,000 | 1,791,000 | 2,702,000 | 371,979 | 327,162 | 323,559 | 186,592 | 297,416 |
| misc current assets | 0 | 0 | 0 | 43,000 | 26,000 | 19,000 | 9,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total current assets | 66,186,000 | 31,523,000 | 18,411,000 | 29,097,000 | 25,932,000 | 19,190,000 | 10,858,000 | 8,676,000 | 4,394,000 | 3,870,210 | 5,111,347 | 3,542,769 | 2,557,081 | 2,135,423 |
| total assets | 315,949,000 | 286,096,000 | 18,463,000 | 29,270,000 | 26,198,000 | 19,604,000 | 11,420,000 | 9,328,000 | 4,552,000 | 4,099,542 | 5,334,688 | 3,698,590 | 2,720,806 | 2,350,618 |
| Bank overdraft | 0 | 0 | 658,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bank loan | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Creditors | 5,760,000 | 3,219,000 | 2,846,000 | 541,000 | 556,000 | 189,000 | 196,000 | 120,000 | 32,000 | 578,207 | 1,062,038 | 698,300 | 359,043 | 1,264,104 |
| Group/Directors Accounts | 10,747,000 | 2,304,000 | 5,301,000 | 0 | 0 | 1,154,000 | 880,000 | 627,000 | 74,000 | 480,185 | 840,503 | 406,851 | 293,186 | 0 |
| other short term finances | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 50,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other current liabilities | 6,959,000 | 4,376,000 | 3,084,000 | 8,366,000 | 10,119,000 | 6,330,000 | 3,144,000 | 2,014,000 | 1,359,000 | 683,503 | 1,477,350 | 1,269,931 | 507,175 | 0 |
| total current liabilities | 23,466,000 | 9,899,000 | 11,889,000 | 8,957,000 | 10,675,000 | 7,673,000 | 4,220,000 | 2,761,000 | 1,465,000 | 1,741,895 | 3,379,891 | 2,375,082 | 1,159,404 | 1,264,104 |
| loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accruals and Deferred Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| provisions | 93,000 | 93,000 | 93,000 | 184,000 | 182,000 | 89,000 | 87,000 | 89,000 | 11,000 | 14,888 | 13,159 | 17,325 | 15,855 | 12,634 |
| total long term liabilities | 93,000 | 93,000 | 93,000 | 92,000 | 91,000 | 89,000 | 87,000 | 89,000 | 11,000 | 14,888 | 13,159 | 17,325 | 15,855 | 12,634 |
| total liabilities | 23,559,000 | 9,992,000 | 11,982,000 | 9,049,000 | 10,766,000 | 7,762,000 | 4,307,000 | 2,850,000 | 1,476,000 | 1,756,783 | 3,393,050 | 2,392,407 | 1,175,259 | 1,276,738 |
| net assets | 292,390,000 | 276,104,000 | 6,481,000 | 20,221,000 | 15,432,000 | 11,842,000 | 7,113,000 | 6,478,000 | 3,076,000 | 2,342,759 | 1,941,638 | 1,306,183 | 1,545,547 | 1,073,880 |
| total shareholders funds | 292,390,000 | 276,104,000 | 6,481,000 | 20,221,000 | 15,432,000 | 11,842,000 | 7,113,000 | 6,478,000 | 3,076,000 | 2,342,759 | 1,941,638 | 1,306,183 | 1,545,547 | 1,073,880 |
| Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||||||||
| Operating Profit | 20,669,000 | 13,989,000 | 6,533,000 | 5,780,000 | 4,362,000 | 3,834,000 | 4,450,000 | 3,387,000 | 828,000 | 517,759 | 842,353 | -309,452 | 672,630 | |
| Depreciation | 18,000 | 23,000 | 95,000 | 264,000 | 172,000 | 188,000 | 208,000 | 150,000 | 103,599,000 | 96,920 | 89,750 | 118,181 | 89,808 | 71,104 |
| Amortisation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Tax | -5,109,000 | -2,714,000 | -1,250,000 | -1,121,000 | -851,000 | -96,000 | -68,000 | 9,000 | -95,000 | -117,236 | -206,898 | 70,347 | -202,304 | |
| Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -642,896 | 642,896 | 0 |
| Debtors | 27,986,000 | 10,355,000 | 5,807,000 | 1,571,000 | 1,515,000 | 6,239,000 | -3,606,000 | 5,193,000 | -1,806,231 | -1,285,954 | 1,564,975 | 1,491,617 | -110,414 | 1,838,007 |
| Creditors | 2,541,000 | 373,000 | 2,305,000 | -15,000 | 367,000 | -7,000 | 76,000 | 88,000 | -546,207 | -483,831 | 363,738 | 339,257 | -905,061 | 1,264,104 |
| Accruals and Deferred Income | 2,583,000 | 1,292,000 | -5,282,000 | -1,753,000 | 3,789,000 | 3,186,000 | 1,130,000 | 655,000 | 675,497 | -793,847 | 207,419 | 762,756 | 507,175 | 0 |
| Deferred Taxes & Provisions | 0 | 0 | -91,000 | 2,000 | 93,000 | 2,000 | -2,000 | 78,000 | -3,888 | 1,729 | -4,166 | 1,470 | 3,221 | 12,634 |
| Cash flow from operations | -7,284,000 | 2,608,000 | -3,497,000 | 1,586,000 | 6,417,000 | 868,000 | 9,400,000 | -826,000 | 106,263,633 | 507,448 | -272,779 | 133,838 | -367,013 | |
| Investing Activities | ||||||||||||||
| capital expenditure | -158,504 | -110,277 | -38,337 | |||||||||||
| Change in Investments | -4,800,000 | 254,485,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| cash flow from investments | -158,504 | -110,277 | -38,337 | |||||||||||
| Financing Activities | ||||||||||||||
| Bank loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Group/Directors Accounts | 8,443,000 | -2,997,000 | 5,301,000 | 0 | -1,154,000 | 274,000 | 253,000 | 553,000 | -406,185 | -360,318 | 433,652 | 113,665 | 293,186 | 0 |
| Other Short Term Loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long term loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hire Purchase and Lease Commitments | 0 | 0 | -50,000 | 50,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other long term liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| share issue | ||||||||||||||
| interest | 570,000 | -2,000 | 38,000 | 135,000 | 79,000 | -10,000 | 3,000 | 7,000 | 0 | 598 | 0 | -259 | 1,341 | |
| cash flow from financing | 581,000 | 249,005,000 | 5,228,000 | 185,000 | -1,075,000 | 1,265,000 | -3,494,000 | 559,000 | -405,944 | -359,720 | 433,652 | 113,406 | 294,527 | |
| cash and cash equivalents | ||||||||||||||
| cash | 6,685,000 | 2,816,000 | -16,450,000 | 1,577,000 | 5,220,000 | 2,083,000 | 5,779,000 | -911,000 | 2,330,021 | 44,817 | 3,603 | 136,967 | -110,824 | 297,416 |
| overdraft | 0 | -658,000 | 658,000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| change in cash | 6,685,000 | 3,474,000 | -17,108,000 | 1,577,000 | 5,220,000 | 2,083,000 | 5,779,000 | -911,000 | 2,330,021 | 44,817 | 3,603 | 136,967 | -110,824 | 297,416 |
iqvia biotech ltd. Credit Report and Business Information
Iqvia Biotech Ltd. Competitor Analysis
Perform a competitor analysis for iqvia biotech ltd. by selecting its closest rivals and benchmarking them against 12 key performance metrics.
iqvia biotech ltd. Ownership
IQVIA BIOTECH LTD. group structure
Iqvia Biotech Ltd. has no subsidiary companies.
Ultimate parent company
IQVIA HOLDINGS INC
#0013898
2 parents
IQVIA BIOTECH LTD.
03299057
iqvia biotech ltd. directors
Iqvia Biotech Ltd. currently has 2 directors. The longest serving directors include Mr Kevin Turland (Feb 2014) and Mr Steven Angus (Mar 2021).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Mr Kevin Turland | United Kingdom | 55 years | Feb 2014 | - | Director |
| Mr Steven Angus | 44 years | Mar 2021 | - | Director |
P&L
December 2022turnover
86m
+45%
operating profit
20.7m
+48%
gross margin
36.5%
+15.81%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
December 2022net assets
292.4m
+0.06%
total assets
315.9m
+0.1%
cash
9.5m
+2.37%
net assets
Total assets minus all liabilities
Similar Companies
iqvia biotech ltd. company details
company number
03299057
Type
Private limited with Share Capital
industry
72110 - Research and experimental development on biotechnology
incorporation date
January 1997
age
27
accounts
Full Accounts
ultimate parent company
previous names
novella clinical ltd (February 2019)
matrix contract research ltd. (July 2009)
incorporated
UK
address
3 forbury place, 23 forbury road, reading, RG1 3JH
last accounts submitted
December 2022
iqvia biotech ltd. Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We found 4 charges/mortgages relating to iqvia biotech ltd.. Currently there are 0 open charges and 4 have been satisfied in the past.
iqvia biotech ltd. Companies House Filings - See Documents
| date | description | view/download |
|---|
